Claims for Patent: 6,265,561

Summary for Patent: 6,265,561

Title:	Sulfotransferase sequence variants
Abstract:	Isolated sulfotransferase nucleic acid molecules that include a nucleotide sequence variant and nucleotides flanking the sequence variant are described. Methods for determining a risk estimate for hormone dependent disease and methods for determining sulfonator status also are described.
Inventor(s):	Weinshilboum; Richard M. (Rochester, MN), Raftogianis; Rebecca B. (Elkins Park, PA), Wood; Thomas C. (Rochester, MN), Otterness; Diane M. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	09/167,681
Patent Claims:	1. An isolated nucleic acid molecule comprising a SULT1A1 nucleic acid sequence, wherein said SULT1A1 nucleic acid sequence comprises a nucleotide sequence variant and nucleotides flanking said sequence variant, and wherein said nucleotide sequence variant is selected from the group consisting of a cytosine at nucleotide 138 of intron 1A, a thymine at nucleotide 34 of intron 5, an adenine at nucleotide 57 of the coding sequence, an adenine at nucleotide 110 of the coding sequence, and an adenine at nucleotide 645 of the coding sequence. 2. The isolated nucleic acid molecule of claim 1, wherein said SULT1A1 nucleic acid sequence encodes a sulfotransferase polypeptide having a glutamine at amino acid residue 37. 3. An isolated nucleic acid molecule comprising a sulfotransferase nucleic acid sequence, wherein said sequence encodes a sulfotransferase allozyme selected from the group consisting of SULT1A1*4, SULT1A2*4, SULT1A2*5, and SULT1A2*6.

Details for Patent 6,265,561

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26